Evidence map›Paper›PMID 28504921›Full record

Trial reportMetabolic syndrome and related disorders2017

Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus.

Omar Bayomy, Ajay D Rao, Rajesh Garg, Anand Vaidya, Alyssa R Kotin, Beata Reiber, Stephanie Nijmeijer, Marcelo F Di Carli, Michael Jerosch-Herold, Raymond Y Kwong and 1 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Metabolic syndrome and related disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Omar Bayomy1 Harvard Medical School , Boston, Massachusetts.
Ajay D Rao1 Harvard Medical School , Boston, Massachusetts.
Rajesh Garg1 Harvard Medical School , Boston, Massachusetts.
Anand Vaidya1 Harvard Medical School , Boston, Massachusetts.
Alyssa R Kotin2 Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Brigham and Women's Hospital , Boston, Massachusetts.
Beata Reiber5 Department of Radiology, Brigham and Women's Hospital , Boston, Massachusetts.
Stephanie Nijmeijer5 Department of Radiology, Brigham and Women's Hospital , Boston, Massachusetts.
Marcelo F Di Carli1 Harvard Medical School , Boston, Massachusetts.
Michael Jerosch-Herold1 Harvard Medical School , Boston, Massachusetts.
Raymond Y Kwong1 Harvard Medical School , Boston, Massachusetts.
Gail K Adler1 Harvard Medical School , Boston, Massachusetts.
Brigham and Women's Hospital · USHarvard University · US

Funding

TRAINING PROGRAM IN HYPERTENSIONT32HL007609 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ADLER, GAIL KURR · 1985 to 2022
$10.2M
Interactions Between Adrenal and Parathyroid Hormones in Human HealthR01DK107407 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI VAIDYA, ANAND · 2015 to 2019
$2.5M
Role of Mineralocorticoid Receptor in Diabetic Cardiovascular DiseaseR01HL087060 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ADLER, GAIL KURR · 2008 to 2011
$2.5M
Aldosterone and Diabetic Cardiovascular Disease: Research and Mentoring ProgamK24HL103845 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI ADLER, GAIL KURR · 2011 to 2021
$1.6M
Vitamin D and Hormonal Mechanisms of Cardiovascular Disease in ObesityK23HL111771 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI VAIDYA, ANAND · 2012 to 2016
$805k
NHLBI NIH HHS K23 HL111771NHLBI NIH HHS K24 HL103845NHLBI NIH HHS R01 HL087060NHLBI NIH HHS T32 HL007609NIDDK NIH HHS R01 DK107407
6 · The paper itself

Abstract

backgroundPlasminogen activator inhibitor-1 (PAI-1) is implicated in the pathophysiology of cardiovascular disease (CVD) and increased in individuals with type 2 diabetes mellitus (T2DM). Adipose tissue produces PAI-1, and pericardial fat is a CVD risk factor. We sought to determine the relationship between PAI-1 and pericardial fat in males and females with well-controlled T2DM.

methodsThe study population consisted of 32 males and 19 females, aged 35-70 years with T2DM, without clinical evidence of CVD or other active medical problems except for hypertension. Subjects were studied under good cardiometabolic control. Study procedures included fasting blood work and cardiovascular imaging. Cardiac magnetic resonance imaging of the heart was used to identify and quantify pericardial fat from the bifurcation of the pulmonary trunk to the last slice containing cardiac tissue.

resultsPAI-1 was positively correlated with pericardial fat (β = 0.72, r = 0.72, P < 0.001) as well as with homeostatic model assessment of insulin resistance (r = 0.31, P = 0.03) and serum triglycerides (r = 0.27, P = 0.05). In a multivariable regression model, controlling for insulin sensitivity, triglycerides, and body mass index, pericardial fat was independently associated with PAI-1 (β = 0.80, P < 0.001).

conclusionsPAI-1 is positively associated with pericardial fat in individuals with T2DM.

Indexed as

Adipose TissueAdiposityAdultAgedCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic AngiopathiesEnalaprilFemaleHumansMaleMiddle AgedPericardiumPlasminogen Activator Inhibitor 1Risk FactorsSimvastatinEnalaprilPlasminogen Activator Inhibitor 1SERPINE1 protein, humanSimvastatinadipose tissuepericardial fatplasminogen activator inhibitor-1type 2 diabetes

Identifiers

PMID28504921
PMCPMC5564011
OpenAlexW2615311387

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.